title: Comparison of hemostatic efficacy for argon plasma coagulation and distilled water injection in treating high-risk bleeding ulcers.
abstract: OBJECTIVE
  Endoscopic treatment is recommended for initial hemostasis in nonvariceal upper gastrointestinal bleeding. Many endoscopic devices have been demonstrated to be effective in the hemostasis of bleeding ulcers. However, the hemostatic efficacy of argon plasma coagulation (APC) has not been widely investigated.
  
  
  METHODS
  From February 2007 to February 2008, 271 consecutive patients with high-risk bleeding ulcers, characterized by active bleeding, nonbleeding visible vessels and adherent clots, were admitted to our hospital. Among these patients, 135 nonrandomly underwent either APC therapy or distilled water injection. Pantoprazole infusion was conducted during the fasting period after endoscopy and orally for 8 weeks to encourage ulcer healing. Episodes of rebleeding were retreated with endoscopic combination therapy. Patients who did not benefit from retreatment underwent emergency surgery.
  
  
  RESULTS
  In all,135 patients were enrolled, among whom 6 with gastric malignancy, acute severe illness or multiple bleeding sites were excluded. Finally, hemostatic efficacy in 59 patients treated with APC was prospectively compared with 70 patients treated with distilled water injection. The two treatment groups were similar with respect to all baseline characteristics. Initial hemostasis was accomplished in 57 patients treated with APC, and 64 patients with distilled water injection therapy (97% vs. 91%, P=0.29). Bleeding recurred in 6 patients treated with APC, and in 17 patients treated with distilled water injection (11% vs. 27%, P=0.03). No significant differences were observed between the 2 groups in hospital stay, transfusion requirements, surgery and mortality.
  
  
  CONCLUSIONS
  Endoscopic therapy with APC is more effective than distilled water injection for preventing rebleeding in the treatment of high-risk bleeding ulcers.
authors.affiliation: Department of Internal Medicine, Kaohsiung Veterans General Hospital, Taiwan.
authors.forename: Huay-Min
authors.initials: HM
authors.lastname: Wang
authors.forename: Ping-I
authors.initials: PI
authors.lastname: Hsu
authors.forename: Gin-Ho
authors.initials: GH
authors.lastname: Lo
authors.forename: Tai-An
authors.initials: TA
authors.lastname: Chen
authors.forename: Lung-Chih
authors.initials: LC
authors.lastname: Cheng
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Chen
authors.forename: Chiun-Ku
authors.initials: CK
authors.lastname: Lin
authors.forename: Hsien-Chung
authors.initials: HC
authors.lastname: Yu
authors.forename: Hoi-Hung
authors.initials: HH
authors.lastname: Chan
authors.forename: Wei-Lun
authors.initials: WL
authors.lastname: Tsai
authors.forename: E-Ming
authors.initials: EM
authors.lastname: Wang
authors.forename: Kwok-Hung
authors.initials: KH
authors.lastname: Lai
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001128:Argon; D005260:Female; D016558:Hemostasis, Endoscopic / Q000379:methods*; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D010438:Peptic Ulcer Hemorrhage / Q000628:therapy*; D011446:Prospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome; D014867:Water / Q000008:administration & dosage*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D014867:Water; D001128:Argon; D000077402:Pantoprazole